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ABSTRACT
Introduction Smoking reduction can lead to increased 
success in quitting. This study aims to determine if a client- 
focused motivational support package for smoking reduction 
(and quitting) and increasing (or otherwise using) physical 
activity (PA) can help smokers who do not wish to quit 
immediately to reduce the amount they smoke, and ultimately 
quit. This paper reports the study design and methods.
Methods and analysis A pragmatic, multicentred, 
parallel, two group, randomised controlled superiority 
clinical trial, with embedded process evaluation and 
economics evaluation. Participants who wished to reduce 
smoking with no immediate plans to quit were randomised 
1:1 to receive either (1) tailored individual health 
trainer face- to- face and/or telephone support to reduce 
smoking and increase PA as an aid to smoking reduction 
(intervention) or (2) brief written/electronic advice to 
reduce or quit smoking (control). Participants in both arms 
of the trial were also signposted to usual local support 
for smoking reduction and quitting. The primary outcome 
measure is 6- month carbon monoxide- confirmed floating 
prolonged abstinence following participant self- reported 
quitting on a mailed questionnaire at 3 and 9 months post- 
baseline. Participants confirmed as abstinent at 9 months 
will be followed up at 15 months.
Ethics and dissemination Approved by SW Bristol 
National Health Service Research Committee (17/SW/0223). 
Dissemination will include publication of findings for the 
stated outcomes, parallel process evaluation and economic 
evaluation in peer- reviewed journals. Results will be 
disseminated to trial participants and healthcare providers.
Trial registration number ISRCTN47776579; Pre-results.
INTRODUCTION
Smoking remains the main cause of prevent-
able morbidity and premature death in 
high- income nations.1 The annual cost of 
smoking in England is estimated to be £11 
billion to society, of which £2.5 billion is to the 
National Health Service (NHS) in England.2 
Strengths and limitations of this study
 ► This is the first study to determine whether offer-
ing support to increase physical activity alongside 
smoking reduction is effective and cost- effective in 
increasing smoking abstinence among smokers not 
immediately ready to quit but who wish to reduce. 
The study involves over 900 participants recruited 
across four sites.
 ► The study’s primary outcome is biochemically veri-
fied 6- month prolonged floating abstinence between 
3 and 9 months post- baseline, with a secondary 
endpoint to consider differences at 15 months.
 ► The intervention involved considerable public in-
volvement in both the pilot and current trial and 
was person- centred, theory based, manualised and 
delivered by eight health trainers who were trained 
to deliver behavioural support, and subsequently re-
motely supervised by phone or Skype.
 ► A mixed- methods process evaluation will explore 
the fidelity of intervention design, delivery, receipt 
and enactment, and explore if and how key compo-
nents in our logic model operated.
 ► As an effectiveness trial, the intervention does not 
involve a supervised exercise programme and some 
participants entering the study may have been more 
interested in smoking reduction rather than in-
creasing physical activity. This may limit the study’s 
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Tobacco control policies and individually targeted inter-
ventions have helped to reduce the UK population 
smoking prevalence rate to 14.7%,3 but prevalence varies 
considerably by socioeconomic and mental health status, 
contributing to growing health inequalities.
The UK’s National Institute for Health and Care Excel-
lence Public Health No. 10 guidelines4 for smoking cessa-
tion focus on identifying a quit date and abrupt cessation, 
with a recognition of the importance of motivational 
support to supplement pharmacological support. For 
those not intending to quit immediately, smoking reduc-
tion may lead to more quit attempts and subsequent 
successful abstinence, though there are limitations in the 
evidence5–8 with a wide range of approaches to reduc-
tion (eg, pharmacological, behavioural support and self- 
initiated approaches). Motivational support appears to 
have the potential to support reduction in smoking, and 
the greater the reduction the greater the likelihood of 
successful quitting.9
The English Smoking Toolkit Study (2011–2014) 
suggests there is interest in smoking reduction, rather 
than immediately quitting, among 50% of smokers, and 
approximately 30% of UK smokers report using e- ciga-
rettes to do so.10 Other evidence- based approaches to self- 
regulate smoking are needed as there remains uncertainty 
over the safety of e- cigarettes.11 There is considerable 
interest in encouraging smokers to acutely and chron-
ically use physical activity (PA) to manage smoking12 13 
though a recent systematic review revealed only 1 of 24 
randomised controlled trials provided evidence that an 
exercise programme can aid abstinence for at least 6 
months14 among those attempting to quit. That said, 
most studies were of low quality and focused on proof 
of concept, rather than being pragmatic and offering an 
acceptable and feasible intervention for smokers more 
generally.
A unique randomised pilot study provided promising 
support for short- term effects of a behavioural support 
intervention offered by a health trainer for increasing PA 
and smoking reduction on cigarettes smoked and absti-
nence.15 16 Previous studies17 have reported that a self- 
determination- based intervention to support autonomy 
and perceived competence for smokers can facilitate 
long- term smoking abstinence, and this approach was 
embedded in the pilot intervention. Intervention partic-
ipants had an average 4.2 sessions by phone or face- to- 
face with the health trainer, with a range of 0–8 sessions. 
Compared with the control group, they were significantly 
more likely to achieve at least a 50% reduction in number 
of cigarettes smoked (39% vs 20%), to attempt to quit 
(22% vs 6%), and be abstinent up to 8 weeks after quit 
day (14% vs 4%) and at 16 weeks (10% vs 4%). A higher 
proportion of the intervention group also reported using 
PA for controlling smoking: 55% vs 22% and 37% vs 16%, 
at 8 and 16 weeks, respectively.15 The intervention costs 
were approximately £192 per participant and exploratory 
cost- effectiveness modelling indicates that the interven-
tion may be cost- effective.15
PA is likely to influence smoking behaviour through 
both implicit and explicit processes.12 A smoker could 
focus on becoming physically active which in turn has 
emotional benefits which may implicitly reduce cognitive 
and emotional triggers for smoking. Exercise may also be 
explicitly used to acutely manage cigarette cravings and 
withdrawal symptoms,18 19 and chronically manage weight 
gain associated with smoking reduction or help in a shift 
towards a healthier identity.
In prospective population surveys and trials, weight 
gain and fear of weight gain is associated with reluc-
tance to quit smoking and remain abstinent, especially 
among women and initially heavier smokers,20–22 with a 
meta- analysis study reporting an average of 4.67 kg (95% 
CI: 3.96 to 5.38) gained after 12 months of abstinence.23 
There is evidence that PA is effective for preventing long- 
term weight gain after smoking cessation,24 not only by 
increased energy expenditure and metabolic rate, but 
also through self- regulation of energy intake, particularly 
emotional snacking.25 Finally, as a result of increasing PA, 
a smoker may begin to establish a different identity (eg, 
investing in personal fitness and generally becoming a 
‘healthy person’), which in turn may trigger a desire to 
reduce harm from smoking through reduction and ulti-
mately quitting.15
Following a successful pilot study15 there is a need 
to establish the effectiveness and cost- effectiveness of 
behavioural support for increasing PA and reducing 
smoking on longer term abstinence among smokers not 
immediately ready to quit.
AIMS & OBJECTIVES
The overarching aim of the trial is to determine if an indi-
vidually tailored behavioural intervention for smokers 
wishing to reduce but not immediately quit provides 
an effective and cost- effective approach to supporting 
increases in PA and smoking reduction, resulting in 
increased rates of quit attempts and subsequent 6- month 
prolonged smoking abstinence.
The specific aims of the trial are to determine whether 
the intervention, compared with support as usual (SAU), 
will:
 ► Increase the proportion of participants who achieve 
6- month prolonged biochemically verified floating 
abstinence at 9 months post- baseline.
 ► Increase the proportion of participants who self- 
report a reduction in number of cigarettes smoked 
(between baseline and both 3 months and 9 months) 
of at least 50%.
 ► Increase the proportion of participants who 
achieve biochemically verified prolonged absti-
nence at 15 months post- baseline (ie, 12 months 
post- intervention).
 ► Increase self- reported PA at 3 and 9 months post- 
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 ► Improve quality of life, self- reported weight and ciga-
rette cravings at 3 and 9 months post- baseline.
Further aims are:
 ► To conduct a health economic evaluation to estimate 
the costs of delivering the intervention and differ-
ences in health and social care costs between inter-
vention and SAU at 9 months post- baseline. This will 
also estimate the cost- effectiveness of the intervention 
compared with SAU at (1) 9 months and (2) over a 
longer term/lifetime horizon.
 ► To conduct an embedded mixed- methods process 
evaluation to explore the mechanisms of action of the 
intervention and acceptability of study processes.
The current paper outlines the protocol for the Trial of 
physical Activity- assisted Reduction of Smoking (TARS) 
trial.
METHODS & ANALYSIS
This protocol is reported in accordance with the Standard 
Protocol Items: Recommendations for Interventional 
Trials guidance26 for protocols of clinical trials and the 
Template for Intervention Description and Replication 
guidelines27 for intervention description.
Study design and setting
The TARS trial is a pragmatic, multicentred, parallel, two 
group, randomised controlled superiority clinical trial 
to compare (1) tailored support to reduce smoking and 
increase PA as an aid to smoking reduction (intervention) 
with (2) brief advice to reduce or quit smoking (control). 
The study includes a mixed- methods embedded process 
evaluation and health economics evaluation. Recruit-
ment to the trial was over 16 months (January 2018–May 
2019) in the geographical areas in and around four cities 
in the UK: Plymouth, Nottingham, London and Oxford.
Study population
Potential participants were approached from primary and 
secondary care establishments and also from the commu-
nity. Participants were adult smokers (≥18 years) who 
smoked ≥10 cigarettes per day (for at least 1 year), wished 
to reduce smoking but not quit immediately. We accepted 
smokers who were also using other nicotine- containing 
or other cigarette management products. Smokers were 
ineligible if they were unable to engage in at least 15 min 
of moderate intensity PA, had any illness or injury that 
might be exacerbated by exercise, were unable to engage 
in the study and/or the intervention due to language or 
for other reasons (eg, provide an unacceptable level of 
risk to the health trainer or researcher). All ineligible 
smokers were referred for smoking cessation advice in 
line with local usual practice.
Study procedures
Participant identification, approach and consent
A broad range of participant identification and approach 
methods were employed in an attempt to reach many 
different demographic groups and make the study 
as inclusive as possible. The most common approach 
method was through a search of a primary care practice 
patient database, with invitations sent to patients who were 
listed as smokers offering them the chance to get in touch 
with the trial team. In the early phase of recruitment, a 
study within a trial was conducted at general practitioner 
(GP) practices at one research site, to compare the effi-
ciency and cost- effectiveness of three different invitation 
methods (full information pack, single- page invite, text 
message).28 Other approaches were via secondary health-
care and stop- smoking services (for those who had failed 
to quit), and by social media, pharmacies, dental prac-
tices, community organisations and local businesses using 
posters and leaflets.
As shown in figure 1 (participant flow chart), smokers 
expressing interest in the trial were screened for eligibility 
by researchers at each site. If suitable and still interested 
in joining the study, participants provided evidence of 
consent either at a face- to- face meeting or via telephone.
Figure 1 Participant flow chart. GP, general practitioner; 
NHS, National Health Service; NICE, National Institute for 
Health and Care Excellence.
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Baseline assessment
Participants then completed a baseline questionnaire with a 
member of the local study team either face- to- face, by mail 
or over the telephone. The schedule of measures and data 
collection at baseline and follow- up are shown in table 1.
Randomisation
Participants were individually randomised to either 
the intervention or control group (1:1 ratio) following 
completion of baseline assessments, to ensure conceal-
ment was preserved. Randomisation was achieved by 
means of a 24- hour web- based system created by the 
UKCRC- registered Peninsula Clinical Trials Unit (CTU) 
in conjunction with a statistician independent from the 
trial team, and used random permuted blocks, with strat-
ification for recruitment site and a dichotomised low/
high score derived from the Heaviness of Smoking Index 
(HSI).29 The HSI score is calculated from summing 
responses to two questions:
1. When the first cigarette is smoked after waking, scored 
as >60 min (score 0); 31–60 min (1); 6–30 min (2) and 
within 5 min (3).
2. How many cigarettes are smoked in a typical day, 
scored as ≤10 cigarettes (0); 11–20 cigarettes (1); 21–
30 cigarettes (2); >30 cigarettes (3).
Total HSI scores of 0–4 were categorised as low, and 5–6 
were considered high for the purposes of stratification.
Following randomisation, all participants were sent a 
letter from the coordinating CTU confirming which trial 
arm they had been assigned to, and a guidance sheet on 
usual support locally for smoking reduction and cessation. 
The participant’s GP was also sent a letter notifying them 
that one of their patients is participating in the study.
Table 1 Schedule of baseline and follow- up measures
Screening and baseline Month 3 Month 9 Month 15*
Demographics (eg, age, gender, education attained, employment status) X       
Self- reported cigarettes per day (or equivalent) X X X X
Reduction of ≥50% in number of cigarettes smoked since baseline†   X X   
Biochemically confirmed abstinence (self- reported quitters only)   X X X
Self- reported floating prolonged abstinence (since quitting smoking, 
with quit date, if relevant) over at least 6 months†
    X X
Accelerometer assessed minutes of moderate and vigorous physical 
activity in a subsample
  X     
Self- reported 7- day recall of physical activity X X X   
Heaviness of Smoking Index X       
Use of smoking management products X X X X
Urge and strength of urge to smoke X X     
Engagement with the health trainer intervention (8 weeks, plus optional 
6 weeks additional support if a quit attempt is made)
  X     
Health and social care utilisation X X X   
Health- related quality of life (EQ- 5D- 5L and SF-12) X X X   
Self- reported weight and height (to calculate BMI) X X X   
Self- reported process measures X X
  Importance and confidence in smoking reduction and cessation     
  Importance and confidence in being physically active
  Action planning to change smoking
  Action planning to change physical activity
  Self- monitoring of smoking
  Self- monitoring of physical activity
  Availability of support to reduce smoking
  Availability of support to increase physical activity
  Use of physical activity for smoking regulation
Serious adverse events (self- reported)   X X   
Qualitative process evaluation (in parallel throughout) (sample) X X X X
*Only participants with biochemically verified abstinence at 9 months are followed- up at 15 months post- baseline.
†Derived measure.
BMI, body mass index; EQ- 5D- 5L, EuroQol-5 dimension-5 level ; SF-12, 12- Item Short Form Health Survey.
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Blinding
It was not possible to blind participants to their allocated 
group. Every effort was made to ensure that the trial team 
remained blind to the allocation of each participant when 
collecting follow- up data (including researchers collecting 
carbon monoxide (CO) measurements), but this was not 
always possible. Health trainers delivering the interven-
tion were obviously aware of the participant’s allocation 
to trial arm, but were discouraged from communicating 
with site researchers about this. Questionnaire booklets 
and accelerometers were mailed out from and returned 
to the CTU without knowledge of trial arm allocation.
Follow-up
At 3 and 9 months post- baseline all participants are 
posted a questionnaire booklet and a freepost envelope 
to return the completed booklet to the CTU. A £20 shop-
ping voucher is mailed to participants on CTU receipt 
of the completed booklets at both 3 and 9 months. To 
increase response rates, motivational postcards are 
mailed to participants before the follow- up question-
naires are sent out. Up to two reminder letters are issued 
(and a further three telephone calls as required) to 
remind participants to return the questionnaire book-
lets, and the option of the participant telephoning a 
member of the research team to aid completion of the 
booklets is offered. Participants are given the option to 
just complete the key questions about smoking behaviour 
if the questionnaire booklet is not returned to the CTU 
within 2 weeks and to submit these responses by email, 
phone or text if preferred to maximise follow- up data 
on key outcomes. If participants do not complete the 
key questions (regardless of method) within a 4- week 
window, they are categorised as not completing follow- up 
at that time point.
All participants who report having made a quit attempt 
in the questionnaire booklet and not smoked since that 
date at 3 and 9 months are contacted for biochemical 
verification of abstinence.
At 3 months post- baseline, approximately 20% of 
participants were sent wrist- worn waterproof acceler-
ometer (GeneActive Original accelerometer, Activin-
sights, Kimbolton, UK, http://www. geneactiv. org/) with 
instructions to wear constantly for 1 whole week (day 
and night), and a freepost return envelope to be sent to 
the CTU. To maximise data completeness, participants 
scheduled to receive an accelerometer were sent a stan-
dardised letter from the CTU, 2 weeks before receiving 
the accelerometer, advising them that they would shortly 
be receiving the device, and asking them to inform the 
CTU if they were unable to wear it. A letter was sent to 
participants who did not object to wearing the device, 3 
days into the 10- day recording period prompting partic-
ipants to start wearing the device if they had not already 
done so. Up to two reminder letters and a follow- up 




The TARS intervention was based on the intervention 
developed for the EARS pilot trial, with further refine-
ment based on feedback from the EARS process evalua-
tion.15 Throughout the development of the intervention 
for the EARS and TARS studies, we engaged with smokers 
from a wide range of socioeconomic backgrounds to 
ensure an acceptable person- centred approach was 
embedded.
Throughout the pilot trial and before commencing 
the definitive trial, we conducted individual and focus 
group discussions with smoking- cessation practi-
tioners, researchers, public health consultants, commu-
nity workers (including volunteers) and people who 
currently or previously smoked. We reviewed literature 
on using exercise as an aid to quitting, and consulted 
with academic experts on behaviour change for physical 
activity, smoking reduction and smoking cessation. These 
activities informed the intervention principles and theo-
retical basis, structure and delivery.
The intervention aimed to be empowering and put 
the client at the centre of the decision- making process. 
All aspects were designed to promote self- determined 
behaviour, focused on elements of self- determination 
theory which emphasises people’s sense of autonomy, 
competence and relatedness.30–32 This was in part 
achieved by adopting motivational interviewing princi-
ples33 as the guiding delivery style for the practitioners 
which have been proposed to enhance and promote self- 
determined behaviour.34
An intervention delivery model, or ‘roadmap’, 
was developed between the pilot and definitive trial 
(figure 2) to aid in the conceptualising of the inter-
vention process and support the manualisation of the 
intervention and training of the practitioners. This was 
supported by the development of a set of ‘core compe-
tencies’ (table 2) developed from the pilot trial which 
outlined key processes, components and behaviour 
change techniques that the health trainers were expected 
to deliver and form the basis of fidelity assessment.35 A 
Figure 2 Indicative map of the TARS intervention 
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comprehensive training manual was developed, outlining 
all the skills, behaviour change techniques and strat-
egies to support behaviour change intended for use in 
the TARS Study. This was used as the basis for a 3- day 
training course, which was delivered by TPT, AT, CG and 
LC. Health trainers then engaged with a wide range of 
‘practice participants’ to complete their training. The 
health trainers attended regular (bi- weekly for the first 3 
months and monthly thereafter) 2- hour formative feed-
back supervision teleconferences throughout the study 
period to help to embed skills and to benefit from each 
other’s shared experiences. Individual supervision for the 
health trainers was available as needed, provided by the 
intervention lead (TPT).
Participants allocated to the intervention arm were 
offered individually tailored behavioural support from a 
health trainer. The health trainer delivered the processes 
outlined in figure 2 and table 2, with the option of up 
to eight weekly sessions, and a further six sessions if the 
participant wanted support after quitting, and aimed 
to empower participants to decide what support was 
offered, and where, when and for how long. Signposting 
to local smoking cessation support services was also 
offered to those wishing to quit. If a smoker wished to 
reduce smoking using e- cigarettes or licensed nicotine- 
containing products (LNCP), they were also offered any 
local available support for this.
Health trainers were appointed on the basis of having 
good communication skills, including empathy, and at 
least some training and experience in supporting health 
behaviour change. All health trainers had at least a first 
degree in a related field although this was not a prerequi-
site for the role. The health trainer was trained to support 
change in both smoking and PA and help individuals to 
make the connections between the two. As described in 
table 2, the core intervention processes that the health 
trainer was trained to deliver were: (1) building rapport 
and supporting autonomous behaviour change; (2) 
building motivation; (3) supporting self- monitoring and 
goal setting; (4) problem solving; (5) integrating smoking 
and PA behaviour; (6) supporting a health identity shift; 
(7) supporting the management of social influence on 
behaviours.
The support offered was broadly structured (based on 
delivering the processes outlined in table 2 and figure 2) 
but health trainers were trained to be flexible in their 
approach, to tailor it for individual needs and prefer-
ences. They were trained to do this using a person- centred 
Table 2 Intervention components, aims, content and indicative change in processes
Intervention components Aim Content Indicative change in processes
Active participant 
involvement (1)
Develop rapport, build 
trust and shared respect.
Effective communication skills. Build 
autonomous support.
Participant feedback on health 
trainer- led support.
Build motivation to reduce 
smoking (2) and increase 
physical activity (3)
Identify ambivalence 
towards reduction and 
quitting. Build self- 
awareness and confidence 
to cut down and increase 
physical activity.
Help smoker to identify importance 
and challenges of reduction and 
cessation, and implicit and explicit 
roles of physical activity (motivational 
interviewing techniques).
Smoker has desire and confidence to 
cut down and perhaps quit over the 
early sessions, and increase physical 
activity. Smoker engages in more 
self- monitor of smoking and physical 
activity behaviour.
Self- monitor smoking and 
physical activity and set 
goals to reduce smoking 
(4) and increase physical 
activity (5)
Develop strategies to 
reduce smoking and 
increase physical activity.
Set SMART goals to reduce 
smoking and increase physical 
activity. Signpost to physical activity 
opportunities and remove barriers to 
do physical activity.
Goals identified and action plans 
developed. Smoker engages in more 
goal setting to reduce smoking and 
increase physical activity behaviour.
Review/problem solving for 
smoking (6) and physical 
activity (7)
Build confidence, 
perceptions of control and 
self- regulation skills.
Smoker reflects on smoking reduction 
and physical activity, identifies 
barriers and possible solutions, 
increases and sets new targets; 
perhaps to quit.
Goals revised to reflect confidence 
to increase physical activity, reduce 
smoking and possibly quit.
Integrating idea of changing 
smoking and physical 
activity (8)
To help smoker to identify 
any links between smoking 
and physical activity
Explore with smoker how physical 
activity may influence smoking (and 
vice versa) (person centred exchange 
of information (Ask–Tell–Discuss)).
Smoker increases use of physical 
activity as an aid to smoking 
reduction.
Reinforce health identity 
shift (9)
To help identify shift 
from smoker to healthier 
identity.
Smoker reflects on label as heavy–
moderate–light or non- smoker status, 
and more active person.
Decrease in importance of smoking 
and increase in importance of doing 
physical activity identified.
Manage social influences on 
smoking (10) and physical 
activity (11)
To involve others in 
process of reducing 
smoking and increasing 
physical activity. Manage 
negative or undermining 
social influences.
Smoker identifies key others who 
can support reduced smoking (or 
cessation) and increasing physical 
activity, and engages with them in 
preferred ways. Uses negotiation and 
discussion to manage negative social 
influences.
Support from others identified as 
important and used for smoking 
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approach and principles from motivational interviewing 
such as showing empathy and reflective listening.36 They 
were also trained to assess (and be aware of) participants’ 
needs in relation to the core psychological needs posited 
by Self- Determination Theory,37 which we referred 
to in the training as ‘the three Cs’: Control (having 
choice/autonomy in decision- making around behaviour 
change); Competence (developing self- efficacy/building 
confidence in the ability to change) and Connectedness 
(social acceptance of the new behaviour/support from 
important others for making changes).
A fuller intervention description, including the trainer 
manual and intervention materials, will be published as 
supplemental materials linked to the final National Insti-
tute for Health Research project report.
Support as usual
Participants allocated to both arms of the trial received 
written guidance for smoking reduction and cessation, 
including web links to what is offered at local level, or 
paper versions of this information. Typically, there are 
no formal programmes for use of medication to support 
reduction (rather than abrupt stopping) and people 
usually buy their own replacement therapy or e- cigarette 
product.
Determination of sample size
Since the planned primary analysis is a comparison 
of the proportions of the binary primary outcome, the 
sample size calculation was based on a two- sided Fisher 
exact test. An abstinence rate of 5% for the control group 
and detectable effect of 6% (ie, an increase from 5% to 
11% due to the intervention) are conservative estimates 
consistent with those from the EARS pilot study15 and 
those reported from a systematic review of pharmaco-
logical interventions.38 The corresponding OR for this 
effect size is 2.35. Participants with missing outcome data 
will be assumed to be still smoking following the Russell 
Standard,39 and the numbers of participants in each allo-
cated group are assumed to be in the ratio of 1:1. Under 
these conditions, according to Stata V.14.2, the minimum 
number of participants required to detect an abstinence 
rate of 11% compared with that of 5% in the control 
group, with a significance level of no more than 5% and 
power of at least 90%, is 900, above which a power in 
excess of 90% is maintained.
Outcome measures
Table 1 lists the outcome measures and when they are 
being assessed.
Primary outcome measure
Biochemically verified 6- month floating prolonged 
abstinence between 3 and 9 months.40 Abstinence will 
be confirmed by expired CO <10 ppm measured with a 
CareFusion MicroCO metre (Williams Medical Supplies, 
Rhymney, UK, www. carefusion. co. uk) at a face- to- face 
visit.
Participants who self- reported abstinence at 3 months 
and who were confirmed as abstinent through biochem-
ical verification via expired CO at a face- to- face assess-
ment and then self- report abstinence (and not having 
smoked even a puff since the 3- month assessment) at 9 
months, again confirmed by expired CO, will be defined 
as having prolonged abstinence over at least 6 months.
Other smoking-related measures
Only participants who have biochemically verified absti-
nence at 9 months are being contacted at 15 months 
post- baseline to assess floating prolonged abstinence 
over a period of 12 months (3–15 months). Participants 
who were not abstinent at 3 months but have biochemi-
cally confirmed abstinence at 9 months will be contacted 
at 15 months to confirm floating prolonged abstinence 
of 6 months between 9 and 15 months. As a contin-
gency measure for verification of abstinence during 
the COVID-19 outbreak, abstinence will be confirmed 
by saliva cotinine level <12 ng/mL41 using a mailed self- 
collection kit and assay provided by ABS Laboratories 
(York, UK, www. acmgloballab. com). This contingency 
measure will apply to follow- up for secondary outcomes 
for a minority of participants. While the intervention is 
expected to primarily influence quitting in the first 3 
months of the study, it is possible that a sustained quit 
attempt occurs after the 3- month assessment as a result 
of the health trainer building behaviour change skills 
which are used subsequently to reduce and then quit 
smoking.
Participants are asked to self- report the number of ciga-
rettes smoked and type of nicotine product (ie, pipes, 
cigars and roll your own). We estimated 0.45 g of tobacco 
was the equivalent of one cigarette based on a previous 
rigorous study42 and reported in the EARS pilot study.15 
From this we will estimate the number of cigarettes 
smoked at follow- up, and also calculate if participants 
reduce smoking by at least 50% between (1) baseline and 
3 months, and (2) baseline and 9 months.
PA measures
The 7- day recall measure of PA43 is used to assess self- 
reported weekly minutes of moderate and vigorous PA. 
An objective measure of total weekly minutes of moderate 
and vigorous PA (MVPA) was collected with a wrist- worn 
waterproof GENEActiv accelerometer44 around the 
3- month follow- up time point. Participants were asked to 
wear the accelerometer on the wrist of the non- dominant 
hand constantly for 1 week and then return to the CTU. 
This accelerometer shows the wearer no information 
about their PA levels and does not have obvious motiva-
tional value.
Physical measures
Participants are asked to self- report their height and 
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Health-related quality of life measures
The EuroQol-5 dimension-5 level (EQ- 5D- 5L) (EuroQol 
Group, 1990) comprises the following five dimensions: 
mobility, self- care, usual activities, pain/discomfort and 
anxiety/depression. Each dimension has five levels: no 
problems, slight problems, moderate problems, severe 
problems and extreme problems.45 The 12- Item Short 
Form Health Survey is a 12- item, patient- reported survey 
of patient health, consisting of 12 questions.46
Resource use/healthcare service use
Use of primary and community- based health and social 
services, and hospital- based inpatient and outpatient 
services are captured using a resource use questionnaire 
developed in two pilot trials involving health trainer- led 
interventions.16 47 It sought to capture the number of 
contacts that occurred (if any) with a range of health and 
social care professionals and where those contacts took 
place since completing the previous survey, using both 
fixed and open format responses. Reasons for hospital 
admissions were also requested.
Self-reported process measures
Single- survey items, using a 5- point Likert scale (strongly 
disagree to strongly agree) assessed the psychological and 
behavioural processes that the intervention was designed 
to influence as shown in table 2. These were used in other 
trials.15 48 49 A single- survey item, using a 6- point scale (not 
at all to all the time), was used to assess frequency of urge 
to smoke in the past week.50 A single survey item (6- point 
Likert scale, no urges to extremely strong) assessed 
strength of urges to smoking in the past week50 as used 
previously.15
Economic evaluation
The economic evaluation will (1) estimate the long- term 
cost- effectiveness of the TARS intervention plus SAU 
versus SAU alone, over a lifetime horizon using a model- 
based economic evaluation, and (2) estimate the cost- 
effectiveness of the TARS intervention plus SAU versus 
SAU alone over the primary 9- month trial follow- up, in an 
economic evaluation conducted alongside the trial. The 
longer term model- based economic analysis is consid-
ered the primary economic analysis, consistent with 
the approach commonly applied in the context of cost- 
effectiveness analysis in smoking cessation settings.
The primary perspective of the economic analyses will 
be that of the NHS and Personal Social Services (ie, third 
party payer), with a broader perspective explored in sensi-
tivity analyses. The primary economic endpoint will be 
the quality- adjusted life- year (QALY, using EQ- 5D data), 
with results presented as incremental cost- effectiveness 
ratios representing estimated costs per QALY gained.
The economic analysis will be undertaken against a 
predefined health economics analysis plan, which is 
available on request. In summary, the trial- based cost- 
effectiveness analysis will use participant- level data 
collected within- trial to estimate (1) the resource use 
and costs associated with the delivery of the TARS inter-
vention, (2) broader resource use and costs associated 
with health and care service use by group, (3) QALYs by 
group, and (4) the incremental cost per unit of outcome 
(eg, cost per incremental QALY, cost per quitter) over the 
9- month follow- up. In this analysis, EQ- 5D- 5L data will 
be used to estimate QALYS, deriving health state values 
at each time point, using the published tariff values for 
England (presently recommendations are for values to be 
derived using methods reported by van Hout et al),51 and 
using the area under the curve approach.52 Analyses will 
be based on an intention- to- treat (ITT) principle, using 
a complete case analysis, and will assess uncertainty and 
include detailed sensitivity analyses.
The model- based economic evaluation will adopt 
a longer term perspective (lifetime) beyond the trial 
follow- up, to present a policy relevant cost- effectiveness 
analyses, that predicts future costs and QALYs after the 
trial endpoint based on the reported effectiveness of the 
TARS intervention. A decision analytic model will be 
used, with the model based on the model developed and 
described in the prior pilot study (EARS),15 which we will 
update and adapt using a review of the recent literature 
on modelling in this area and based on input from a stake-
holder group. The model- based evaluation will be based 
on good practice guidelines for decision analytic model-
ling in the health technology assessment context.53–55
Embedded mixed-methods process evaluation
A mixed- methods process evaluation will focus on trial 
processes and methods, and will attempt to understand 
the effective components and processes of the interven-
tion. During the internal pilot phase, the evaluation will 
focus on barriers and facilitators for recruitment methods, 
initial intervention engagement and early intervention 
implementation. For the subsequent main trial, the eval-
uation will focus on acceptability of study processes (via 
a qualitative substudy), intervention engagement levels, 
predictors of intervention engagement, intervention 
delivery fidelity and evaluating the implementation of the 
intervention process model (participant understanding 
of the intervention model (receipt fidelity), mediating 
effects of process measures on PA and smoking outcomes 
(enactment fidelity), mediating effects of PA on smoking 
outcomes, approaches and acceptability of smoking 
reduction, multiple behaviour change, progression to 
cessation and other perceived effectual intervention 
components).
Data for the process evaluation will be collected via: the 
trial database, audio recordings of intervention sessions, 
and audio recorded and transcribed interviews with trial 
participants, research assistants, health trainers and GPs/
practice managers.
Trial data handling
Data are collected and maintained in accordance with 
the current legal and regulatory requirements. A data 
management protocol has been produced by the CTU to 
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ensure secure data collection and storage in accordance 
with the Data Protection Act 1998, and later conforming 
to the General Data Protection Regulation 2016 and Data 
Protection Act 2018.
Electronic study records will be held over the lifetime 
of the study in secure storage solutions aligned with 
the host institution’s information security classification 
policy. At the time of writing, electronic study data are 
stored in an SQL server database on a restricted access, 
secure server maintained by the University of Plym-
outh. Data are entered into the database via a bespoke 
web- based data entry system encrypted using SSL V.3 
(QuoVadis Global, http://www. quovadisglobal. com). 
Access to identifiable information is restricted and 
permission- based.
A parallel, linked, bespoke data system has been used 
to manage intervention engagement post- randomisation. 
The system captures all health trainer attempted and 
actual contact with intervention participants in real time 
to produce summary data (eg, number of sessions, dura-
tion and mode of sessions, notes on session content), and 
aid supervision sessions and intervention management 
(eg, should a health trainer be unavailable).
Identifiable information will be omitted from the tran-
scriptions of the process evaluation interviews.
Statistical analysis plan
A detailed statistical analysis plan was drafted during 
the trial delivery phase and will be approved by an inde-
pendent statistician and wider Trial Steering Committee 
(TSC), prior to database lock. The analyses will be 
reported in full and in accordance with the Consolidated 
Standards of Reporting Trials (CONSORT) guidelines.56 
The main planned analyses are summarised below.
Baseline characteristics and summary statistics
Descriptive statistics by allocated group will be presented 
for the baseline, and primary and secondary outcomes, 
which includes the smoking outcomes and questionnaire 
data as well as the smoking and physical mediators, with 
the exception of the primary outcome and secondary 
abstinence measures (assessed at 3, 9 and 15 months only) 
and accelerometer outcomes (assessed only at 3 months).
For continuous outcomes, summary information will 
be presented in the form of means alongside SDs. Count 
and skewed continuous data will be presented in terms 
of median and IQR. For categorical outcomes, summary 
information will be presented in the form of frequencies 
and percentages.
Inferential statistical comparison at baseline of 
randomised groups is not good practice57 and it is 
expected that participants in both groups will, on average, 
be similar. Following initial primary analysis, if substantial 
imbalance at baseline is identified in any key variables, 
such as gender and age, the importance of any imbalance 
will be noted and additional adjusted analyses may be 
performed.
Primary analysis
The null hypothesis is that there is no difference in CO 
verified 6- month prolonged floating abstinence rates 
between the intervention and control groups at 9 months 
post- baseline. In line with the Russell Standard schedule,39 
the primary comparative analysis will be conducted on an 
ITT basis, in which participants with missing responses 
will be considered to still be smokers. Interpretation of 
the primary effectiveness analysis will be based on the OR 
from the logistic regression model adjusted for (fixed 
effect) stratification variables: site as a factor and HSI as 
an ordinal covariate. Both the adjusted (primary analysis) 
and unadjusted ORs and corresponding 95% CIs will be 
presented. Primary effectiveness shall also be presented 
as a relative risk along with the absolute between- group 
differences in abstinence rates, as recommended in the 
CONSORT guidelines for parallel group randomised 
trials.58
Planned sensitivity analysis of the primary outcome:
a. Rather than assuming participants with missing re-
sponses at 3 or 9 months were still smoking, the prima-
ry outcome will be imputed under a number of varying 
assumptions and the primary analysis re- run for each 
of the scenarios.
b. A complier average causal effect analysis will be under-
taken, if greater than 20% of participants allocated to 
the intervention group are categorised as not having 
completed at least two intervention sessions with a 
health trainer, with individual participants in the in-
tervention group categorised as compliers if they com-
pleted at least two intervention sessions. Participants 
in the control group and non- compliers in the inter-
vention group will be compared with compliers in the 
intervention group.
Secondary analyses
To explore whether the primary outcome was influenced 
by the intervention dose actually received (ie, number of 
health trainer sessions attended), the primary outcome 
shall be modelled on the number of health trainer sessions 
attended in the intervention group only, adjusting for the 
stratification variables. Although the trial is not powered 
to detect the influence of moderating factors on the 
primary outcome, secondary analyses will be undertaken 
to explore whether the intervention effect is modified 
by key demographic and/or behavioural factors at base-
line. These are prespecified as the postcode- based Index 
of Multiple Deprivation (IMD); the factor indicating 
smoking cessation medication or a vaping product at 
baseline; MVPA level, confidence to quit; and the stratifi-
cation variable, HSI. The multivariable logistic regression 
model outlined above will be extended to include the 
interaction term of allocated group and each of the listed 
potential modifying variables. Evidence of an interaction 
shall be interpreted through the 95% CIs of the coeffi-
cient for the interaction term.
During the development of this study, the potential 
health trainer effect was considered at length. Given the 
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lack of evidence on individual health trainer effects, the 
study design and sample size calculations do not allow 
for such partial clustering within health trainers (within 
recruitment sites). However, an exploratory analysis of 
the intervention effect will be undertaken using a multi-
level, mixed- modelling approach, to allow for the partially 
nested data: participants allocated to the intervention 
group will be partially clustered within the health trainer, 
in turn nested within sites.
Analysis of secondary outcomes
Between- group comparisons will be undertaken, 
including for the following key secondary outcomes:
 ► Biochemically verified point prevalence abstinence at 
3, 9 and 15* months post- baseline.
 ► Self- reported point prevalence abstinence at 3, 9 and 
15* months post- baseline.
 ► Prolonged biochemically verified abstinence over 6 
months between 9 and 15 months post- baseline.
 ► Prolonged biochemically verified abstinence for 
at least 12 months between 3 and 15 months post- 
baseline (derived from biochemically confirmed 
abstinence at all three follow- up time points).
 ► At least a 50% reduction in reported smoking levels 
between (1) baseline and 3 months, and (2) baseline 
and 9 months.
 ► Number of cigarettes used on an average day over the 
past week (including equivalent cigars, tobacco) at 3, 
9 and 15* months post- baseline.
 ► Total number of LNCP used on an average day over 
the past week at 3, 9 and 15* months post- baseline.
 ► Total number of self- reported minutes engaged 
in MVPA over the past week at 3 and 9 months 
post- baseline.
 ► BMI at 3 and 9 months post- baseline.
NB: * only for those with biochemically confirmed 
abstinence at 9 months.
The following data are derived from accelerometers 
mailed to a subgroup of participants in both arms of the 
trial along with the 3- month questionnaire, which are 
returned after the accelerometers have been worn for 
7 days:
 ► The average time spent in moderate to vigorous 
activity over the past week.
 ► The average daily time spent sleeping over the past 
week.
No adjustment for multiple analyses will be made; such 
adjustment methods are too conservative when outcomes 
are positively correlated, as they would be in this trial. 
Analyses will use multivariable linear regression (contin-
uous outcomes) or logistic regression (binary outcomes) 
to compare each of these secondary outcomes between 
allocated groups, with adjustment for site as a factor, and 
HSI, as an ordinal variable, as well as baseline values of 
the outcome as appropriate. As accelerometer data were 
only available at 3 months, only summary statistics for 
weekly minutes of MVPA shall be presented by allocated 
group without adjustment for baseline variables.
The between- group comparisons of continuous 
outcomes will be reported as mean differences together 
with 95% CIs, unless the outcomes are substantially 
skewed. Both adjusted and unadjusted differences will 
be presented. The between- group comparisons of binary 
outcomes will be reported as the adjusted and unadjusted 
ORs with conversion to relative risks and corresponding 
CIs, along with the absolute between- group differences in 
abstinence rates.
Analyses will be undertaken to investigate whether 
any effect of the intervention in terms of reduction in 
smoking at 3 months and 9 months is modified by key 
sociodemographic and/or behavioural factors at base-
line. These prespecified factors at baseline are using 
smoking management medication or vaping, IMD, the 
stratification variables, MVPA level and confidence 
to quit. The multivariable models will be extended to 
include the interaction term of allocated group and each 
of the potential modifying variables.
Model checking
The logistic regression model for the primary analysis is 
prespecified. However, observations identified as poten-
tial outliers through their influence on the model, may 
be excluded as part of a sensitivity analysis. The distri-
butional assumptions of multivariable linear regression 
models will be visually assessed through plots of residuals. 
If there are concerns about distributional assumptions 
being met, bootstrapped CIs for the adjusted between- 
group differences will be produced.
Mediational analysis
If there is evidence that the intervention is effective, 
an exploratory mediational analysis will be undertaken 
to determine if any effect of allocated group on the 
primary outcome was mediated by changes in smoking 
and/or physical activity between baseline and 3- month 
follow- up, adjusted for the stratification variables (site 
and HSI). Further analyses will explore if changes in 
smoking and physical activity are mediated by changes in 
outcomes from the questionnaire on attitudes to smoking 
between baseline and 3 months (importance and confi-
dence to reduce smoking/increase physical activity; self- 
monitoring and goal setting; urges to smoke).
DISCUSSION
The manuscript describes the methods involved in the 
trial design and intervention delivered.
Patient and public involvement
The TARS research team has worked with people who 
smoke, not as research participants, individually and in 
groups from across all communities, to guide research 
questions and study design, and conduct intervention 
development and dissemination over the past 15 years. 
As an example of their input, they had varying views on 
the merits of vaping to reduce smoking and how various 
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forms of PA may help. A university employee and non- 
employee patient and public involvement (PPI) group 
(of people who currently or have previously smoked) 
regularly met to input into intervention and trial methods 
development. There was further PPI input into Project 
Management Group (PMG) meetings and TSC meetings 
throughout the trial. The study team has also engaged 
with key stakeholders involved in commissioning and 
delivering community interventions to assess where the 
proposed intervention would best fit and the study team 
will continue to do this prior to and during intervention 
development.
Trial monitoring and oversight
The trial PMG includes a multidisciplinary team of clini-
cians and researchers with expertise in all aspects of trial 
design, intervention development and delivery, conduct, 
analysis and quality assurance. The TSC involves indepen-
dent expertise to help guide the trial on behalf of the 
funders and provide oversee trial progress. The TSC will 
also sign off the Statistical and Health Economic Anal-
yses Plans. The Data Monitoring Committee (DMC) 
provides independent expertise and support particu-
larly regarding evidence or reason why the trial should 
be amended or terminated based on recruitment rates, 
compliance, safety or efficacy.
Ethics and dissemination
The study has been approved by the South West–Central 
Bristol Research Ethics Committee (REC reference: 17/
SW/0223) and the Health Research Authority. A number 
of approvals have been granted for minor and substantial 
amendments; the amendment history and full details of 
the amendments are available on request.
The research team will work with stakeholders and 
PPI representatives at each site, and nationally, to help 
to interpret the results and the implications for policy 
and practice. The PMG will establish a publication plan 
and authorship rules. Reporting will follow current 
CONSORT guidelines for randomised trials. The study 
results will be submitted for publication in relevant inter-
national, high impact, peer- reviewed journals. Names of 
key collaborators and groups who have contributed to the 
trial will be clearly stated in all publications. The study 
findings will be presented at regional, national and inter-
national meetings as appropriate.
Safety considerations
The recording and reporting of non- serious adverse 
events (AEs) in this low- risk study is not required. Serious 
AEs (SAEs) will be documented from the time of partic-
ipant consent until a maximum of 8 weeks after the 
follow- up assessment at 9 months. A protocol for iden-
tifying, reporting and managing SAEs has been estab-
lished by the CTU, in conjunction with the PMG, DMC 
and TSC, and conforms to the requirements of the trial 
sponsor and NHS REC.
Access to data
The CTU Data Manager is the custodian of the final trial 
data set, with the exception of the audio files and tran-
scripts arising from qualitative interviews with partici-
pants which are held by the process evaluation team.
Access will be granted to the sponsor and host institu-
tion for the purposes of study- related monitoring, audits 
and inspections.
Members of the study team will have restricted access to 
the anonymised dataset for the purposes of conducting 
the trial, and to undertake the statistical and economic 
data analysis and the process evaluation.
Data requests should be submitted to the corresponding 
author for consideration. Following publication of the 
primary results of the trial, access to available anonymised 
data may be granted depending on review of the data 
request and appropriate agreements being in place.
Current study status
The TARS Study completed participant recruitment in 
May 2019. Data collection for the 9- month and 15- month 
follow- up assessments are expected to be completed in 
April and October 2020, respectively, and results are 
expected to be published in mid-2021.
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